ArticleBMC medical genomics2026
Global distribution of mcr-carrying bacteria: an analysis of genomic data.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic Insights into the Population Structure and Antimicrobial Resistance of the Most Prevalent Human-Associated Non-TyphoidalMicroorganisms · 2026Article
- Genomic characterization of an extensively drug-resistant Klebsiella pneumoniae co-harboring mcr-3.11, blaNDM-5 and blaCTX-M-27 isolated from pelvic effusion in a colon cancer patient.BMC microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMobilized colistin resistance (mcr) gene has emerged as a major driver of colistin resistance. Therefore, this study aimed to determine the distribution of mcr-variants and mcr-carrying genomes deposited in the NCBI database by sample collection periods and across continents, countries, genera, species, and ecosystems.
methodsIn this database mining study, the keyword "mcr" was used to identify all mcr-carrying genomes deposited in the NCBI Pathogen Detection database until June 07, 2025, 12h15 GMT. A purely descriptive approach was used in this study, and percentages were calculated by dividing the number of an event by the total number of events (percentage = n/Nx100).
resultsOf the 2422739 whole genomes registered in the NCBI database, 18785 (0.78%) carried complete mcr variant sequences. Seventy-seven mcr subvariants were detected, including mostly mcr-1.1 (9431/18785; 50%), and mcr-9.1 (5971/18785; 32%). Mcr-9.1 was the most frequently detected subvariant in several genera, including Serratia spp. (17/17; 100%), Cronobacter spp. (155/160; 97%), and Pluralibacter spp. (19/20; 95%), whereas mcr-1.1 was the most commonly detected subvariant in Escherichia and Shigella spp. (8235/9678; 85%). Regarding geographical distribution, mcr-1.1 was the most observed subvariant in Asia (6759/9033; 75%) and Europe (1886/4680; 40%), whereas mcr-9.1 was the most identified in America (2982/4017; 74%) and Oceania (546/771; 71%). In Africa, mcr-10.1 (52/160; 33%), and mcr-1.1 (50/160; 31%) were the most frequent subvariants. Mcr-carrying genomes deposited in the NCBI database were distributed across ecosystems, including humans (n = 8185), animals (n = 4521), the environment (n = 468), and food (n = 48). The sample collection years for mcr-carrying bacteria ranged from 1953 to 2025, and the distribution of mcr-carrying genomes was as follows: 1953-1990 (n = 49), 1991-1999 (n = 47), 2000-2009 (n = 704), 2010-2019 (n = 12810), and 2020-2025 (n = 4297). Another key finding was that 705 of the 18785 mcr-carrying genomes deposited in the NCBI database (3.8%) harbored multiple mcr genes, including 693 and 12 genomes co-carrying two and three mcr genes, respectively.
conclusionMcr-carrying bacteria represent a significant One Health concern because of their major role in colistin resistance and potential for global dissemination. Key actions, such as global surveillance, One Health monitoring, and appropriate stewardship, should be taken to preserve the efficacy of colistin for decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.